Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration

A. W. Bianco, P. D. Constable, B. R. Cooper, Sandra D. Taylor

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are an integral component of equine analgesia, yet currently available NSAIDs are both limited in their analgesic efficacy and have adverse effects. The NSAID ketorolac tromethamine (KT) is widely used in humans as a potent morphine-sparing analgesic drug but has not been fully evaluated in horses. The purpose of this study was to determine the pharmacokinetic profile of KT in horses after intravenous (i.v.), intramuscular (i.m.), and oral (p.o.) administration. Nine healthy adult horses received a single 0.5-mg/kg dose of KT via each route of administration. Plasma was collected up to 48 h postadministration and analyzed for KT concentration using HPLC/MS/MS. Noncompartmental analysis of i.v. dosage indicated a mean plasma clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady-state of 0.77 L/kg. Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively. The drug was rapidly absorbed after i.m. and p.o. administration, and mean bioavailability was 71% and 57% for i.m. and p.o. administration, respectively. Adverse effects were not observed after i.v., i.m., and p.o. administration. More studies are needed to evaluate the analgesic and anti-inflammatory properties of KT in horses.

Original languageEnglish (US)
Pages (from-to)167-175
Number of pages9
JournalJournal of Veterinary Pharmacology and Therapeutics
Volume39
Issue number2
DOIs
StatePublished - Apr 1 2016

PubMed: MeSH publication types

  • Journal Article
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration'. Together they form a unique fingerprint.

  • Cite this